Dealroom

VitriVax raises $87M for Lyme vaccine

Cover art for VitriVax raises $87M for Lyme vaccine

TL;DR: VitriVax raised $87 million Series C to pursue Lyme disease vaccine after no approved human vaccine exists. VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine. VitriVax raised $87 million Series C to develop Lyme disease vaccine. No approved human Lyme vaccine exists, creating unmet need for new solution.

Nov 18, 2026

From · · 30s

TL;DR: VitriVax raises $87M for Lyme vaccine

VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine.

VitriVax raised $87 million Series C to pursue Lyme disease vaccine after no approved human vaccine exists. VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine. VitriVax raised $87 million Series C to develop Lyme disease vaccine. No approved human Lyme vaccine exists, creating unmet need for new solution.

  • Funding round
  • Market gap

Read the story version — the same reporting as a swipeable deck of 3 cards.

Read the original on Dealroom

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on vitrivax and related topics.